Navigation Links
Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

cipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... BEIJING , Aug. 3 /PRNewswire-Asia-FirstCall/ ... CCM ), operator of the largest,network of radiotherapy ... report its unaudited financial results for the second,quarter ended ... August 18, 2010 .,Concord Medical,s management will hold an ...
... BETHESDA, Md. , Aug. 2 /PRNewswire-Asia/ -- ... independent American provider of Western,healthcare products and services in the People,s ... quarter fiscal 2011,financial results on Monday, August 9, 2010 , before ... ET that day to discuss,financial results. , ...
Cached Medicine Technology:Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 2Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 3Chindex International to Report First Quarter 2011 Financial Results 2
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... healing, but the numbers tell a different story. Too ... they,ve been admitted, and hospital-related infections continue to be ... , Now, a radical new high-tech software program developed ... is now catching on faster than the flu. ...
... to Include Solutions for Medical Equipment, Facility,Design, ... More, DALLAS and NEW YORK, Nov. ... with Siemens Corporation to provide a wide,range ... next generation of,physician-owned healthcare environments., (Logo: ...
... 3 Will Use Tobacco Settlement Money to Keep ... V. Corr, Executive Director, Campaign for,Tobacco-Free Kids, ... delivered a victory for the state,s kids and ... that will reduce smoking, save lives,and lower health ...
... of leukemia patient,s DNA may lead to routine gene ... -- In a genetics first, researchers report that ... person with acute myelogenous leukemia. , There were some ... already identified genetic alterations, were associated with the blood ...
... of Georgia announced today that it has received a ... Melinda Gates Foundation. The grant will support an ... A. Koni titled "Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 ... 104 grants recently announced by the Gates Foundation for ...
... LINTHICUM, Md., Nov. 5 Dialysis Corporation,of America ... has amended its secured,revolving credit facility with KeyBank ... financing. The three-year agreement provides for both,base rate ... based, respectively,upon either the bank,s base rate or ...
Cached Medicine News:Health News:Reducing epic proportions 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 3Health News:North Dakota Votes to Keep Promise to Kids by Fully Funding Tobacco Prevention 2Health News:First-Ever Mapping of Cancer Patient's Genome 2Health News:First-Ever Mapping of Cancer Patient's Genome 3Health News:MCG receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Dialysis Corporation of America Announces $25 Million Credit Facility 2
... The STA Compact CT is ... analyzer capable of performing clotting ... The system's unique method of ... and rapid processing of STAT ...
... synthesized in the parafollicular C-cells of the ... granules. The major action of calcitonin is ... osteoclast activity, resulting in decreased mobilization of ... most evident in conditions associated with high ...
... 68 kDa protein, which is produced primarily during ... sac [1]. Human fetal serum AFP levels ... reach 19-26 g/min during mid-gestation (14-20 weeks). ... AFP continue to increase after mid-gestation, a gradual ...
... (hCG) is a two chain (alpha- and ... tissue of the placenta and is normally ... Produced by the trophoblastic epithelium of the ... luteum in the early stages of pregnancy. ...
Medicine Products: